BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25256312)

  • 1. MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients.
    Ress AL; Stiegelbauer V; Winter E; Schwarzenbacher D; Kiesslich T; Lax S; Jahn S; Deutsch A; Bauernhofer T; Ling H; Samonigg H; Gerger A; Hoefler G; Pichler M
    Mol Carcinog; 2015 Nov; 54(11):1442-50. PubMed ID: 25256312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients.
    Pichler M; Ress AL; Winter E; Stiegelbauer V; Karbiener M; Schwarzenbacher D; Scheideler M; Ivan C; Jahn SW; Kiesslich T; Gerger A; Bauernhofer T; Calin GA; Hoefler G
    Br J Cancer; 2014 Mar; 110(6):1614-21. PubMed ID: 24504363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsa-miR-875-5p exerts tumor suppressor function through down-regulation of EGFR in colorectal carcinoma (CRC).
    Zhang T; Cai X; Li Q; Xue P; Chen Z; Dong X; Xue Y
    Oncotarget; 2016 Jul; 7(27):42225-42240. PubMed ID: 27302926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA XIST facilitates proliferation and epithelial-mesenchymal transition of colorectal cancer cells through targeting miR-486-5p and promoting neuropilin-2.
    Liu A; Liu L; Lu H
    J Cell Physiol; 2019 Aug; 234(8):13747-13761. PubMed ID: 30656681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of miR-193a-5p correlates with lymph node metastasis and poor prognosis in colorectal cancer.
    Zhang P; Ji DB; Han HB; Shi YF; Du CZ; Gu J
    World J Gastroenterol; 2014 Sep; 20(34):12241-8. PubMed ID: 25232258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mir-145-5p is a suppressor of colorectal cancer at early stage, while promotes colorectal cancer metastasis at late stage through regulating AKT signaling evoked EMT-mediated anoikis.
    Cheng X; Shen T; Liu P; Fang S; Yang Z; Li Y; Dong J
    BMC Cancer; 2022 Nov; 22(1):1151. PubMed ID: 36348305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53-induced miR-30e-5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1.
    Laudato S; Patil N; Abba ML; Leupold JH; Benner A; Gaiser T; Marx A; Allgayer H
    Int J Cancer; 2017 Nov; 141(9):1879-1890. PubMed ID: 28656629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-145-5p suppresses proliferation, metastasis and EMT of colorectal cancer by targeting CDCA3.
    Chen Q; Zhou L; Ye X; Tao M; Wu J
    Pathol Res Pract; 2020 Apr; 216(4):152872. PubMed ID: 32107086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4.
    Cheng D; Zhao S; Tang H; Zhang D; Sun H; Yu F; Jiang W; Yue B; Wang J; Zhang M; Yu Y; Liu X; Sun X; Zhou Z; Qin X; Zhang X; Yan D; Wen Y; Peng Z
    Oncotarget; 2016 Jul; 7(29):45199-45213. PubMed ID: 27286257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNHG14 promotes the tumorigenesis and metastasis of colorectal cancer through miR-32-5p/SKIL axis.
    Ye T; Zhang N; Wu W; Yang B; Wang J; Huang W; Tang D
    In Vitro Cell Dev Biol Anim; 2019 Dec; 55(10):812-820. PubMed ID: 31471872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. lncRNA SNHG1 cooperated with miR-497/miR-195-5p to modify epithelial-mesenchymal transition underlying colorectal cancer exacerbation.
    Bai J; Xu J; Zhao J; Zhang R
    J Cell Physiol; 2020 Feb; 235(2):1453-1468. PubMed ID: 31276207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-485-5p as a potential biomarker and tumor suppressor in human colorectal cancer.
    Pan Y; Qin J; Sun H; Xu T; Wang S; He B
    Biomark Med; 2020 Feb; 14(3):239-248. PubMed ID: 31984757
    [No Abstract]   [Full Text] [Related]  

  • 14. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
    Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
    J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIRT2, a direct target of miR-212-5p, suppresses the proliferation and metastasis of colorectal cancer cells.
    Du F; Li Z; Zhang G; Shaoyan S; Geng D; Tao Z; Qiu K; Liu S; Zhou Y; Zhang Y; Gu J; Wang G; Li L; Wu W
    J Cell Mol Med; 2020 Sep; 24(17):9985-9998. PubMed ID: 32697380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-196a-5p promotes metastasis of colorectal cancer via targeting IκBα.
    Xin H; Wang C; Liu Z
    BMC Cancer; 2019 Jan; 19(1):30. PubMed ID: 30621631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Mir-452-5p Overexpression in Epithelial-Mesenchymal Transition (EMT) in Early-stage Colorectal Cancer.
    Koyama Y; Fujihara S; Chiyo T; Matsui T; Hamaya S; Fujita K; Tani J; Morishita A; Kobara H; Ono M; Iwama H; Masaki T
    In Vivo; 2023; 37(5):1980-1990. PubMed ID: 37652512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer.
    Li H; Dai S; Zhen T; Shi H; Zhang F; Yang Y; Kang L; Liang Y; Han A
    Eur J Cancer; 2014 Apr; 50(6):1207-21. PubMed ID: 24412052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-146a suppresses the expression of CXCR4 and alters survival, proliferation and migration rate in colorectal cancer cells.
    Afshar-Khamseh R; Javeri A; Taha MF
    Tissue Cell; 2021 Dec; 73():101654. PubMed ID: 34601384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression.
    Ye YP; Wu P; Gu CC; Deng DL; Jiao HL; Li TT; Wang SY; Wang YX; Xiao ZY; Wei WT; Chen YR; Qiu JF; Yang RW; Lin J; Liang L; Liao WT; Ding YQ
    Oncotarget; 2016 Sep; 7(38):61312-61324. PubMed ID: 27494869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.